Zydus Lifesciences Receives VAI Classification from FDA

  Published 1 year ago

Zydus Lifesciences received a VAI classification from the USFDA after an April 2025 inspection at its Dabhasa API facility, now closed.

  • Inspection conducted April 21-25, 2025, at Dabhasa facility near Vadodara for API manufacturing.
  • VAI classification requires voluntary corrective actions, not formal FDA enforcement actions.
  • Inspection closed by FDA with no immediate regulatory actions or warnings indicated.

You might like these

India's Poverty Drop: 269 Million Lifted Out of Extreme Poverty

Adani Launches India's First Off-Grid Green Hydrogen Plant

Titan Intech Joins MIC for Mini-LED Tech

Investors Dominate U.S. Home Sales Amid High Rates

Blinkit Overtakes Zomato in Sales

BIAL Plans Rs 46.3B Bond Raise

GAIL Q1 FY26 Profit Drops 26%

News that matters the most ⚡